Inovio Stock Continues To Surge: What's Going On?
Portfolio Pulse from Adam Eckert
Inovio Pharmaceuticals Inc's stock is surging after the FDA allowed the company to use data from the completed Phase 1/2 trial of INO-3107 for a Biological License Application (BLA) for accelerated approval. The company will not need to conduct a planned Phase 3 trial for the submission. However, a confirmatory trial will be required before the submission. If approved, INO-3107 would be the first DNA medicine in the U.S. and the first Inovio candidate to be approved.
October 11, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inovio's stock is likely to continue its upward trend in the short term due to the positive news from the FDA. However, the company noted that changes to the development plan for INO-3107 could impact prior cash runway guidance.
The FDA's positive feedback is a significant development for Inovio, which is likely to boost investor confidence and drive the stock price up in the short term. However, the company's note about potential impact on cash runway guidance due to changes in the development plan for INO-3107 introduces a degree of uncertainty.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100